Barclays PLC Has $289,000 Stock Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX)

Barclays PLC lifted its stake in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) by 341.1% during the third quarter, Holdings Channel reports. The firm owned 58,067 shares of the company’s stock after purchasing an additional 44,903 shares during the quarter. Barclays PLC’s holdings in TScan Therapeutics were worth $289,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Bank of Montreal Can acquired a new stake in shares of TScan Therapeutics during the second quarter worth $749,000. Bank of New York Mellon Corp purchased a new position in shares of TScan Therapeutics during the second quarter valued at $682,000. State Street Corp grew its holdings in shares of TScan Therapeutics by 24.4% during the third quarter. State Street Corp now owns 756,499 shares of the company’s stock valued at $3,767,000 after buying an additional 148,414 shares in the last quarter. Stifel Financial Corp grew its holdings in shares of TScan Therapeutics by 3.9% during the third quarter. Stifel Financial Corp now owns 99,133 shares of the company’s stock valued at $494,000 after buying an additional 3,733 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of TScan Therapeutics during the third quarter valued at $112,000. 82.83% of the stock is owned by institutional investors and hedge funds.

TScan Therapeutics Stock Performance

TCRX opened at $3.07 on Monday. The company has a market cap of $163.85 million, a PE ratio of -2.90 and a beta of 0.79. The stock has a 50-day moving average of $4.12 and a 200-day moving average of $5.28. TScan Therapeutics, Inc. has a 52-week low of $2.60 and a 52-week high of $9.69. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.03. The company had revenue of $1.05 million during the quarter, compared to the consensus estimate of $2.86 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. As a group, equities research analysts forecast that TScan Therapeutics, Inc. will post -1.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on TCRX. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of TScan Therapeutics in a report on Wednesday, December 11th. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of TScan Therapeutics in a research note on Wednesday, December 11th. Finally, Wedbush restated an “outperform” rating and issued a $7.00 target price on shares of TScan Therapeutics in a research note on Monday, December 23rd.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.